Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYLYNK-008: Pembrolizumab and Olaparib in Squamous NSCLC
NCT03976362Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2019
- Primary completion
- Sep 2023
- Countries
- 20
01
Overview
A Phase 3 trial of olaparib in non-small cell lung cancer, squamous cell carcinoma (NSCLC), sponsored by Merck & Co.. Started Jun 2019; status: completed.
02
Drugs
olaparib
03
Conditions
non-small cell lung cancer, squamous cell carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT03976362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03976362.